183 related articles for article (PubMed ID: 21321976)
1. Development of a brain metastatic canine prostate cancer cell line.
Thudi NK; Shu ST; Martin CK; Lanigan LG; Nadella MV; Van Bokhoven A; Werbeck JL; Simmons JK; Murahari S; Kisseberth WC; Breen M; Williams C; Chen CS; McCauley LK; Keller ET; Rosol TJ
Prostate; 2011 Sep; 71(12):1251-63. PubMed ID: 21321976
[TBL] [Abstract][Full Text] [Related]
2. Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.
Simmons JK; Dirksen WP; Hildreth BE; Dorr C; Williams C; Thomas R; Breen M; Toribio RE; Rosol TJ
Prostate; 2014 Sep; 74(13):1251-65. PubMed ID: 25043424
[TBL] [Abstract][Full Text] [Related]
3. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
[TBL] [Abstract][Full Text] [Related]
4. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
LeRoy BE; Thudi NK; Nadella MV; Toribio RE; Tannehill-Gregg SH; van Bokhoven A; Davis D; Corn S; Rosol TJ
Prostate; 2006 Aug; 66(11):1213-22. PubMed ID: 16683269
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
Wang Z; Wang J; Li X; Xing L; Ding Y; Shi P; Zhang Y; Guo S; Shu X; Shan B
Int J Oncol; 2014 Oct; 45(4):1469-78. PubMed ID: 25051198
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
7. Animal models of bone metastasis.
Rosol TJ; Tannehill-Gregg SH; LeRoy BE; Mandl S; Contag CH
Cancer; 2003 Feb; 97(3 Suppl):748-57. PubMed ID: 12548572
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
Williams S; Pettaway C; Song R; Papandreou C; Logothetis C; McConkey DJ
Mol Cancer Ther; 2003 Sep; 2(9):835-43. PubMed ID: 14555702
[TBL] [Abstract][Full Text] [Related]
9. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
10. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein.
Blomme EA; Dougherty KM; Pienta KJ; Capen CC; Rosol TJ; McCauley LK
Prostate; 1999 May; 39(3):187-97. PubMed ID: 10334108
[TBL] [Abstract][Full Text] [Related]
11. The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Elshafae SM; Kohart NA; Altstadt LA; Dirksen WP; Rosol TJ
Prostate; 2017 May; 77(7):776-793. PubMed ID: 28181686
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis.
Xu J; Wang R; Xie ZH; Odero-Marah V; Pathak S; Multani A; Chung LW; Zhau HE
Prostate; 2006 Nov; 66(15):1664-73. PubMed ID: 16902972
[TBL] [Abstract][Full Text] [Related]
14. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
15. Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.
Christian PA; Thorpe JA; Schwarze SR
Cancer Biol Ther; 2009 Jan; 8(1):73-80. PubMed ID: 19029816
[TBL] [Abstract][Full Text] [Related]
16. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Sato A; Asano T; Ito K; Asano T
J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
[TBL] [Abstract][Full Text] [Related]
18. Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.
Li Q; Yin L; Jones LW; Chu GC; Wu JB; Huang JM; Li Q; You S; Kim J; Lu YT; Mrdenovic S; Wang R; Freeman MR; Garraway I; Lewis MS; Chung LW; Zhau HE
Oncotarget; 2016 Dec; 7(51):84645-84657. PubMed ID: 27835867
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Shapovalov Y; Benavidez D; Zuch D; Eliseev RA
Int J Cancer; 2010 Jul; 127(1):67-76. PubMed ID: 19894220
[TBL] [Abstract][Full Text] [Related]
20. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
Al Nakouzi N; Bawa O; Le Pape A; Lerondel S; Gaudin C; Opolon P; Gonin P; Fizazi K; Chauchereau A
Neoplasia; 2012 May; 14(5):376-87. PubMed ID: 22745584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
